|
Hi! For us at T2B and probably for most of you, too, September is not only the return from summertime, but also the turn around the corner that takes us through the end of the year and into JPM. This year feels especially jam-packed, so before anything else, I want to thank everyone who joined us at our T2Bmeets last week along the Eastern Seaboard, in D.C., Philly, and Boston for making the time — time away from work, client deadlines, family, travel, and everything else competing for it. A few special thank-you's for our Boston meetup:... to the Alkermes Corporate Affairs team for welcoming us into your space, being terrific hosts, and continuing to be such engaged members of the T2B community. ... to Biosector 2 for your generous support of the evening and of T2B. ... to Andrew Law, Gretchen Murphy, Carlo Tanzi, and Alina Worth for such a candid, practical conversation about how we keep companies relevant when the obvious milestones can be few and far between. ... to Carly Goldsmith, Deb Becker, and Kim Meninger for experimenting with us re: our first-ever Coaches Corner, with speed-coaching sessions. I loved being able to offer another way for people to use the evening to invest in themselves. 10 takeaways from last week's "staying relevant between milestones" panel discussion:1. Fight for mind share. An investor's juggling 50 or 100 names, and suddenly going quiet is how you slide down the list. 5. Start with who needs to hear it. Classic, right? It's worth repeating: The same news reads differently to an investor and a patient community, so sort the audience before the channel, and of course, lean on legal and reg to ensure compliance. Thanks again to everyone who made last week's mixers meaningful. I hope you left with a few new ideas, a few new connections, and maybe a little more space to think. See you next time, Lynnea P.S. - If you're in the SF Bay Area, join us TOMORROW (September 22nd) @ Exelixis for our local mixer, and if you're in San Diego, hope to see you at next week's meetup (September 30th)! |
Hi! Patients and patient advocacy organizations show up across biopharma communications in all kinds of ways: sharing lived experience, reviewing materials, advising teams, participating in research, speaking at events, and helping organizations better understand the communities they serve. At our August Comm Convo, Rethinking What We Ask of Patients, we took a closer look at what makes those engagements thoughtful, useful, and sustainable. A huge thank you to Erin Murphy (Alagille Syndrome...
Hi! We communicators seek to become -- and remain -- trusted advisors to the C-suite, whether at our own organizations or at our client companies. But we don’t often hear from the executive receiving that counsel what was useful, what changed their thinking, what missed the mark, and what happened once the comms team left the room. So, for the opening session of our 2nd Annual Virtual Biopharma Comm Forum, we’re flipping the usual format to hear from a CEO. On Tuesday, October 6th, Jodie...
Hi! Depending on how you define the sector, there are thousands of biopharma companies -- and many more organizations across the broader life sciences ecosystem. That’s a lot of employers competing for increasingly specialized talent. And when so many can point to great science, meaningful work, and the opportunity to make a difference, standing out certainly isn’t easy. AI is adding another layer. Candidates can now use AI tools to research potential employers, which means their first...